



ASX ANNOUNCEMENT

18 December 2018

CardieX Group Company inHealth Executes Letter of Intent with Global Electronics and Medical Device Company

Highlights:

- Execution of Letter of Intent ("LOI") with leading global electronics and medical device company ('GEMDC').
- GEMDC is a multi-ten-billion USD market cap "household brand" company with a wide range of product and service offerings across the health technology ecosystem.
- Parties to develop telehealth programs and products across GEMDC's line of medical and consumer products with an initial focus on chronic sleep disorders.
- Global sleep apnea market forecast to be a US\$6.5 Billion market by 2023 – up from US\$4.4 Billion in 2018.
- Major sleep apnea companies looking to differentiate offerings to patients and health professionals via services such as telehealth.
- inHealth's sleep telehealth programs to be sold by GEMDC through sleep physicians and direct to consumer and are expected to be materially financially accretive to inHealth and CardieX.
- Companies bound by NDA in respect of the corporate identity of GEMDC and any further details at this stage for purposes of maintaining confidentiality and competitive advantage. Identification of the parties and further details will be provided at product launch in Q1, 2019.

CardieX Limited (ASX: CDX, the Company) is pleased to announce that its group company inHealth has signed an LOI with one of the world's leading brand electronic and medical device companies.

Under the LOI the parties will initially work together to develop telehealth programs for managing the chronic sleep disorder conditions of GEMDC 's consumer customers as well as



providing those same programs to practitioners for sale directly to their patients. The parties will then work towards rolling out similar programs across the range of GEMDC's global health product and service offerings.

Jointly developed programs will be branded under GEMDC's name and are expected to be significantly financially accretive to inHealth and CardieX in 2019. The parties are now working towards formal contract and are bound by a Non-Disclosure Agreement in terms of any further disclosures at this time.

CardieX CEO, Craig Cooper commented, "Through this partnership inHealth will deliver a new and differentiated health solution to the market, and tap into the rapidly growing demand for performance-based, whole-person health. This opportunity combines the clinically based telehealth programs of inHealth with a leading global household brand such as GEMDC to increase GEMDC's product sales and significantly extend the lifetime value of their customer – a win-win for all."

For more information please contact:

Chief Executive Officer
Craig Cooper
Ph: +61 429 993 399
ccooper@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

About inHealth

inHealth, Inc is a leading US provider of telehealth services, providing digital, e-commerce, and mobile tools for patients to connect online with health coaches as part of a patient care program. inHealth's patient care programs are based on long-term clinical trials that demonstrate superior patient outcomes through the use of telehealth coaching services. inHealth has partnerships with some of the leading healthcare institutions in the USA including Anthem, American Well, and Kaiser Permanente.